ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors.

The Team and Advisors combines scientific, business, legal, and technology expertise, spanning the entire process of drug development from translational science through preclinical and clinical drug development.

ViroStatics intends to license its compounds at the preclinical stage, with a patent protection to be extended until 2043.

The Coronavirus pandemic (COVID-19)

ViroStatics is an independent contract testing laboratory specialized in the analysis in vitro of any substance and device in an appropriate cell system to determine its efficacy as an ANTIVIRAL against SARS-CoV-2 coronavirus.

SARS-CoV-2 caused outbreaks of illness mainly because of person-to-person transmission via close contacts and droplets produced by an infected person’s cough or sneeze. ViroStatics has developed a bioaerosol system in order to test nebulised drug treatments, inhalers, disinfectants or devices for virucidal activity in a state-of-the-art Biosafety Level 3 facility, according to the US CDC guidelines to identify countermeasures to minimise risk of infection.

COVID-19 is in everyone’s mind and heart. We assure you that we are putting all our forces into action to fight it.